Milan J Sonneveld (M J Sonneveld)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 20

Top Topics

Hepatitis B Virus

Dendritic Cells

Prognostic Factors

Top Venues

Journal of viral hepatitis

Alimentary pharmacology & therapeutics

Hepatology (Baltimore, Md.)

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Milan J Sonneveld, Fatemeh Parouei, Caroline den Hoed, Jeroen de Jonge, Morteza Salarzaei, Robert J Porte, Harry L A Janssen, Marieke de Rosner-van Rosmalen, Serge Vogelaar, Adriaan J van der Meer, Raoel Maan, Sarwa Darwish Murad, Wojciech G Polak, Willem Pieter Brouwer
Graft Steatosis and Donor Diabetes Mellitus Additively Impact on Recipient Outcomes After Liver Transplantation-A European Registry Study. Clinical transplantation 38 (8) (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis (2024)
Mina S Farag, Margo J H van Campenhout, Milan J Sonneveld, Scott Fung, Karel J van Erpecum, David K Wong, Elke Verhey, Robert de Man, Robert J De Knegt, Johannes T Brouwer, Hubertus C Baak, Jordan J Feld, Kin Seng Liem, André Boonstra, Bettina E Hansen, Harry L A Janssen
Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study). Journal of viral hepatitis 31 (4) (2024)
Laurens A van Kleef, Milan J Sonneveld, Fang Zhu, M Arfan Ikram, Maryam Kavousi, Robert J de Knegt
Liver stiffness is associated with excess mortality in the general population driven by heart failure: the rotterdam study. Liver international : official journal of the International Association for the Study of the Liver (2023)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Laurens A van Kleef, Milan J Sonneveld, Robert J de Knegt
Reply. Hepatology (Baltimore, Md.) (2022)
Filip De Ridder, Milan J Sonneveld, Oliver Lenz, Harry L A Janssen, Willem Talloen, Bettina E Hansen
Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials. Journal of viral hepatitis 28 (11) (2021)
Sylvia M Brakenhoff, Robert A de Man, Robert J de Knegt, Harry L A Janssen, Milan J Sonneveld
Editorial: HBV cure-the quest for biomarkers to predict off-treatment sustained response. Authors' reply. Alimentary pharmacology & therapeutics 53 (4) (2021)
Milan J Sonneveld, Willem Pieter Brouwer, Robert A de Man, Harry L A Janssen, null null
Letter: rates and determinants of significant liver inflammation in chronic hepatitis B virus-infected patients with low ALT levels in the absence of significant fibrosis-authors' reply. Alimentary pharmacology & therapeutics 53 (1) (2021)
Milan J Sonneveld, Benjamin Maasoumy
Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European gastroenterology journal (2021)
Raoel Maan, Milan J Sonneveld
Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test. Alimentary pharmacology & therapeutics 53 (8) (2021)
Hannah S J Choi, Milan J Sonneveld, Mina S Farag, Willem Pieter Brouwer, Sylvia M Brakenhoff, Grishma Hirode, Adam J Gehring, Rob A de Man, Bettina E Hansen, Harry L A Janssen
Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. Journal of viral hepatitis 28 (12) (2021)
Sylvia M Brakenhoff, Robert A de Man, André Boonstra, Margo J H van Campenhout, Robert J de Knegt, Florian van Boemmel, Annemiek A van der Eijk, Thomas Berg, Bettina E Hansen, Harry L A Janssen, Milan J Sonneveld
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Alimentary pharmacology & therapeutics 53 (2) (2020)
Milan J Sonneveld, Willem Pieter Brouwer, Bettina E Hansen, Henry Lik Yuen Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Rong-Nan Chien, Hannah Choi, Robert J de Knegt, Cynthia Wat, Vedran Pavlovic, Anuj Gaggar, Qing Xie, Maria Buti Ferret, Robert A de Man, Harry L A Janssen, null null
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Alimentary pharmacology & therapeutics 52 (8) (2020)
Milan J Sonneveld, Robert J de Knegt
Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Alimentary pharmacology & therapeutics 51 (1) (2020)
Boris J B Beudeker, Zwier M A Groothuismink, Robert A de Man, Caroline D M Witjes, Annemiek A van der Eijk, André Boonstra, Milan J Sonneveld
Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV-associated early-stage hepatocellular carcinoma: results from a Dutch long-term follow-up study. Journal of viral hepatitis 28 (1) (2020)
Milan J Sonneveld, Gertine W van Oord, Margo J H van Campenhout, Robert A De Man, Harry L A Janssen, Robert J de Knegt, André Boonstra, Annemiek A van der Eijk
Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. Journal of viral hepatitis 26 (7) (2019)